Follow
Alejandro Berlin
Alejandro Berlin
Clinician-Scientist, Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto
Verified email at rmp.uhn.ca
Title
Cited by
Cited by
Year
Genomic hallmarks of localized, non-indolent prostate cancer
M Fraser, VY Sabelnykova, TN Yamaguchi, LE Heisler, J Livingstone, ...
Nature 541 (7637), 359-364, 2017
5802017
Spatial genomic heterogeneity within localized, multifocal prostate cancer
PC Boutros, M Fraser, NJ Harding, R De Borja, D Trudel, E Lalonde, ...
Nature genetics 47 (7), 736-745, 2015
5172015
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study
E Lalonde, AS Ishkanian, J Sykes, M Fraser, H Ross-Adams, N Erho, ...
The lancet oncology 15 (13), 1521-1532, 2014
3742014
An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report
DE Spratt, WH Beeler, FY de Moraes, LD Rhines, JJ Gemmete, ...
The Lancet Oncology 18 (12), e720-e730, 2017
2682017
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression
S Chen, G Zhu, Y Yang, F Wang, YT Xiao, N Zhang, X Bian, Y Zhu, Y Yu, ...
Nature cell biology 23 (1), 87-98, 2021
2262021
ONECUT2 is a driver of neuroendocrine prostate cancer
H Guo, X Ci, M Ahmed, JT Hua, F Soares, D Lin, L Puca, A Vosoughi, ...
Nature communications 10 (1), 278, 2019
1802019
A prostate cancer “nimbosus”: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies
MLK Chua, W Lo, M Pintilie, J Murgic, E Lalonde, V Bhandari, ...
European urology 72 (5), 665-674, 2017
1702017
Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer
M Fraser, A Berlin, RG Bristow, T Van der Kwast
Urologic Oncology: Seminars and Original Investigations 33 (2), 85-94, 2015
1322015
A systematic review of the evidence for the decipher genomic classifier in prostate cancer
NK Jairath, A Dal Pra, R Vince Jr, RT Dess, WC Jackson, JJ Tosoian, ...
European urology 79 (3), 374-383, 2021
1122021
Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer
C McIntosh, L Conroy, MC Tjong, T Craig, A Bayley, C Catton, ...
Nature medicine 27 (6), 999-1005, 2021
1002021
Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials
MP Deek, K Van der Eecken, P Sutera, RA Deek, V Fonteyne, AA Mendes, ...
Journal of clinical oncology 40 (29), 3377, 2022
922022
Prognostic role of Ki-67 score in localized prostate cancer: a systematic review and meta-analysis
A Berlin, JF Castro-Mesta, L Rodriguez-Romo, D Hernandez-Barajas, ...
Urologic Oncology: Seminars and Original Investigations 35 (8), 499-506, 2017
912017
Implementation and outcomes of virtual care across a tertiary cancer center during COVID-19
A Berlin, M Lovas, T Truong, S Melwani, J Liu, ZA Liu, A Badzynski, ...
JAMA oncology 7 (4), 597-602, 2021
822021
Stereotactic ablative radiotherapy for the management of spinal metastases: a review
RM Glicksman, MC Tjong, WFP Neves-Junior, DE Spratt, KLM Chua, ...
JAMA oncology 6 (4), 567-577, 2020
792020
The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited
MP Deek, K Van der Eecken, R Phillips, NR Parikh, PI Velho, TL Lotan, ...
European urology 80 (5), 632-640, 2021
752021
Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial
NM Richard, LJ Bernstein, WP Mason, N Laperriere, C Maurice, BA Millar, ...
Journal of Neuro-Oncology 142, 565-575, 2019
672019
Low-grade prostate cancer: time to stop calling it cancer
SE Eggener, A Berlin, AJ Vickers, GP Paner, H Wolinsky, MR Cooperberg
Journal of Clinical Oncology 40 (27), 3110-3114, 2022
572022
Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis
RM Glicksman, U Metser, D Vines, J Valliant, Z Liu, PW Chung, ...
European urology 80 (3), 374-382, 2021
572021
Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging …
RT Dess, K Suresh, MJ Zelefsky, SJ Freedland, BA Mahal, ...
JAMA oncology 6 (12), 1912-1920, 2020
562020
Challenges and opportunities in primary CNS lymphoma: A systematic review
MN Kerbauy, FY Moraes, BH Lok, J Ma, LN Kerbauy, DE Spratt, ...
Radiotherapy and Oncology 122 (3), 352-361, 2017
542017
The system can't perform the operation now. Try again later.
Articles 1–20